Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bhide

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Scientific Reports|June 8, 2017
A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other EtiologiesD L Sampson, B A Fox, T D Yager, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitorsZhen-Wei Cai, Donna Wei, Robert M Borzilleri, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitorsRobert M Borzilleri, Zhen-Wei Cai, Christopher Ellis, et al.
Molecular Cancer Therapeutics|January 28, 2010
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinasesRajeev S Bhide, Louis J Lombardo, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complexSoong-Hoon Kim, Keith L Constantine, Gerald J Duke, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|March 1, 2017
Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planningF Guerreiro, N Burgos, A Dunlop, et al.
Journal of Medicinal Chemistry|June 10, 2005
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitorsRobert M Borzilleri, Xiaoping Zheng, Ligang Qian, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2Robert M Borzilleri, Rajeev S Bhide, Joel C Barrish, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitorsLouis J Lombardo, Amy Camuso, John Clark, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2016
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitorsRajeev S Bhide, James Neels, Lan-Ying Qin, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Scientific Reports|June 8, 2017
A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other EtiologiesD L Sampson, B A Fox, T D Yager, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitorsZhen-Wei Cai, Donna Wei, Robert M Borzilleri, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitorsRobert M Borzilleri, Zhen-Wei Cai, Christopher Ellis, et al.
Molecular Cancer Therapeutics|January 28, 2010
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinasesRajeev S Bhide, Louis J Lombardo, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complexSoong-Hoon Kim, Keith L Constantine, Gerald J Duke, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|March 1, 2017
Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planningF Guerreiro, N Burgos, A Dunlop, et al.
Journal of Medicinal Chemistry|June 10, 2005
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitorsRobert M Borzilleri, Xiaoping Zheng, Ligang Qian, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2Robert M Borzilleri, Rajeev S Bhide, Joel C Barrish, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitorsLouis J Lombardo, Amy Camuso, John Clark, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2016
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitorsRajeev S Bhide, James Neels, Lan-Ying Qin, et al.
Pageof 5